From: The multiplex bead array approach to identifying serum biomarkers associated with breast cancer
Clinicopathological Concentration of biomarkers factors (mean ± SD) | P value | ||
---|---|---|---|
T stage | T1 to 2 (n = 85) | T3 to 4 (n = 13) | Â |
   A1AT (ng/ml) |    4059.69 ± 6175.49 |    550.85 ± 712.09 | 0.001 |
   EGF (ng/ml) |    265.71 ± 200.59 |    452.23 ± 221.82 | 0.017 |
   ApoH (μg/ml) |    122.83 ± 30.97 |    144.18 ± 31.13 | 0.023 |
N stage | N0 (n = 32) | N1 to 3 (n = 66) | Â |
   sVCAM-1 (ng/ml) |    672.13 ± 109.22 |    755.17 ± 188.23 | 0.007 |
   Transthyretin (ng/ml) |    160.62 ± 55.99 |    185.54 ± 58.18 | 0.047 |
M stage | M0 (n = 90) | M1 (n = 8) | Â |
   proApoA1 (μg/ml) |    27.38 ± 9.28 |    19.63 ± 13.41 | 0.032 |
ER expression | Negative (n = 52) | Positive (n = 44) | Â |
   A2M (μg/ml) |    66.73 ± 23.27 |    82.51 ± 31.51 | 0.006 |
   Vitronectin (ng/ml) |    5458.08 ± 3224.21 |    4126.95 ± 1508.43 | 0.012 |
   Transthyretin (ng/ml) |    187.61 ± 57.12 |    162.24 ± 51.31 | 0.025 |
   HMWK (ng/ml) |    16767.50 ± 12263.40 |    22483.41 ± 14115.87 | 0.035 |
   PAI-1 (ng/ml) |    20.22 ± 7.06 |    17.51 ± 5.68 | 0.043 |
PR expression | Negative (n = 34) | Positive (n = 62) | Â |
   A2M (μg/ml) |    65.59 ± 19.03 |    78.56 ± 31.52 | 0.031 |
   CA19-9 (U/ml) |    27.16 ± 19.19 |    78.89 ± 187.35 | 0.035 |
c-erbB2 expression | Negative (n = 42) | Positive (n = 53) | Â |
   sVCAM-1 (ng/ml) |    770.21 ± 197.73 |    696.91 ± 143.80 | 0.047 |
   SAA (ng/ml) |    2427.74 ± 250.48 |    5813.77 ± 11884.32 | 0.048 |